“得福组合”肺癌治疗新进展 2025 ASTRO大会公布安罗替尼系列研究成果

Core Insights - The 67th American Society for Radiation Oncology (ASTRO) annual meeting showcased significant research findings from Zhengda Tianqing regarding Anlotinib in lung cancer treatment, particularly in small cell lung cancer (SCLC) [1] Group 1: Research Findings - Anlotinib combined with whole-brain radiotherapy (WBRT) demonstrated improved intracranial progression-free survival (iPFS) of 9.9 months and overall survival (OS) of 14.6 months in patients with brain metastases from SCLC [1] - The "Defu Combination" (Anlotinib and TQB2450) showed a 12-month progression-free survival rate of 86.7% and a total survival rate of 100% in limited-stage SCLC patients after chemoradiotherapy [2] - A Phase II trial indicated that Anlotinib combined with radiotherapy for locally advanced non-small cell lung cancer (NSCLC) patients intolerant to concurrent chemoradiotherapy resulted in a 1-year progression-free survival rate of 78.3% and an overall survival rate of 78.0% [3][4] Group 2: Safety and Efficacy - The safety profile of Anlotinib in combination with WBRT showed manageable adverse events, with the most common being fatigue (57.5%) and hypertension (52.5%), without any grade 4 adverse events reported [1] - In the study involving TQB2450 and Anlotinib, no disease progression was observed in the limited-stage SCLC patients, indicating a durable clinical benefit and controllable safety [2] - The combination of Anlotinib and radiotherapy for NSCLC patients showed a low incidence of severe adverse events, with 20% experiencing grade 3-4 hematological adverse reactions and no grade 5 events reported [4]